Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 3
2007 pubmed

Expression and immunolocalisation of antimicrobial peptides within human palatine tonsils.

Ball. S L SL; Siou. G P GP; Wilson. J A JA; Howard. A A; Hirst. B H BH; Hall. J J

Key Findings

  • Tonsils express LL‑37, beta‑defensins 1‑3, LEAP‑1, LEAP‑2, and other antimicrobial peptides
  • All six peptides were found in every tonsil sample examined
  • Patients with recurrent tonsillitis showed reduced surface levels of LL‑37, beta‑defensin 1, and beta‑defensin 3 compared to healthy controls
  • First report of LEAP‑2 expression in human tonsils

Practical Outcomes

  • Boosting your innate immunity—e.g., through vitamin D supplementation, which can increase LL‑37 production—might help reduce susceptibility to tonsil infections. However, the study does not provide a direct dosing protocol, so any interventions are speculative and should be approached cautiously.

Summary

The study found that human tonsils naturally produce several antimicrobial peptides, including LL‑37, which help defend against infections. People with recurrent tonsillitis had lower levels of LL‑37 and some other peptides on the surface of their tonsils, which might make them more prone to infections.

Abstract

Recurrent acute tonsillitis is one of the most frequent ENT referrals, yet its pathogenesis remains poorly understood, and tonsillectomy still costs the National Health Service more than pound 60,000000 annually. Antimicrobial cationic peptides are components of the innate immune system. They are generally small, highly positively charged peptides with broad spectrum antimicrobial activity which function as the body's 'natural antibiotics'. The role of antimicrobial cationic peptides in the susceptibility of patients to recurrent acute tonsillitis is unknown. To characterise and compare antimicrobial cationic peptide expression and localisation in human palatine tonsils from control subjects and recurrent acute tonsillitis patients, and to assess the potential role of these peptides in the pathogenesis of tonsillitis. Palatine tonsils were harvested with informed consent from 19 recurrent acute tonsillitis patients and from five control subjects undergoing tonsillectomy for sleep disorders. Total ribonucleic acid was isolated and antimicrobial cationic peptide expression was characterised using reverse transcription polymerase chain reaction. Fluorescent immunohistochemical techniques were used to localise antimicrobial cationic peptides within fresh frozen tonsil sections. Using molecular analyses, the palatine tonsils from control and recurrent acute tonsillitis subjects were confirmed as a site of expression of the antimicrobial cationic peptides human beta-defensin 1-3, LL-37 (cathelicidin) and Liver expressed antimicrobial peptide-1 (LEAP-1). We also demonstrated for the first time the expression of Liver expressed antimicrobial peptide-2 (LEAP-2). Our analyses indicated that all six antimicrobial cationic peptides were expressed in all 26 tonsil samples. Immunohistochemical staining indicated that the antimicrobial cationic peptides were localised to the tonsil surface and crypt epithelium. However, the surface epithelium of tonsils from recurrent acute tonsillitis patients showed reduced amounts of antimicrobial peptides human beta-defensins 1 and 3, and LL-37, compared with healthy controls. The tonsil epithelium synthesizes an array of antimicrobial cationic peptides which function as host defence. Preliminary immunohistochemical data suggest that the surface epithelium of tonsils from recurrent acute tonsillitis patients contains reduced amounts of such peptides, which may increase these patients' susceptibility to infection.

Study Information

Provider

pubmed

Year

2007

Date

2007-02-26T00:00:00.000Z

DOI

10.1017/s0022215107006184